A real-world retrospective analysis to evaluate the efficacy and safety of surufatinib in the treatment of advanced neuroendocrine neoplasms in China.

Variables with numerically higher hazards – including primary tumor outside the pancreas (HR 2.037, P = 0.351), concomitant immunotherapy (HR 1.275, P = 0.648), time from diagnosis to surufatinib ≥6 months (HR 1.291, P = 0.634), prior systemic anti-tumor therapy (HR 1.428, P = 0.520), chemotherapy (HR 2.635, P = 0.076), and hypertension (HR 1.457, P = 0.496) – also did not reach statistical significance.

also in 111,027 other papers